Newsletter Subject

There’s Still Time to Invest in CV-19 Vaccine Stocks

From

tradewins.com

Email Address

kimwaller@tradewins.com

Sent On

Wed, Jun 9, 2021 10:00 PM

Email Preheader Text

Other Exciting News Wake Up! Your Potential Profits Ride On How You Enter Your Trade! If you?re a

[Logo] June 9, 2021 [www.tradewins.com]( Other Exciting News Wake Up! Your Potential Profits Ride On How You Enter Your Trade! If you’re a short-term trader, everything rides on how you get into your trade. That’s the simple truth. And nobody’s talking about it... until now! [[Download Your FREE eBook] How To Enter YOUR Next Trade The Right Way!]( My name’s Lee Gettess and I’ve spent most of my 30+ year career behind the scenes… trading for myself, consulting with major institutions, and designing automated trading system for the rich & powerful. Researching and developing makes my days just fly by, and I love what I do. I wouldn’t trade my life with anyone’s. I feel truly blessed. But something has been bothering me… I’m not sure if it is due to an influx of new traders during the pandemic, but I have seen a lot of discussion lately that suggests to me many traders are just a little… well, sloppy… with how they enter a market... It is extremely important. The entry is the one-and-only time you enjoy the luxury of demanding EXACTLY what you want before taking action… and it can be a real game-changer! So, I wrote this book to help traders like you. I hope you enjoy it… [[Download FREE eBook] How To Enter YOUR Next TradeThe Right Way!]( You need to grab this free ebook now [CLICK HERE](. Sincerely, Lee Gettess Recent Articles [There’s Still Time to Invest in CV-19 Vaccine Stocks]( by [Ian Cooper]( [Higher Interest Rates are Bad for Stock Markets]( by [Steve Swanson]( [KeyPoint Market Daily]( by [Joe Duffy]( [TradeWins Author Team]( Tomorrow, you could begin doubling your account every single month starting with one letter. The letter will come from a 20-year trading professional named Ian Cooper. He says, “In 2017, following my trades you would be doubling even tripling your account some months. Let me show you how.” He will show you exactly what to do... and he’ll give you the blueprint for just $1. [Get Daily Trade Alert Now]( About TradeWins [Inside Trading Newsletter]( [Webinars]( [Videos]( [Trading Strategy]( [Options]( [Futures]( [Forex]( [Day Trading]( [Subscription Services]( [E-Books]( [Customer Satisfaction Survey 2020]( There’s Still Time to Invest in CV-19 Vaccine Stocks by [Ian Cooper]( [image](#) In the U.S., life is beginning to return to normal. In fact, thanks to the vaccines, daily new infections and deaths are down. Unfortunately, it’s still a major problem for other parts of the world. As noted by The Washington Post, “The emergence of more virulent variants of the virus in countries like Brazil and India and the slowness of vaccination efforts in many places outside the West have contributed to deadly new waves. Coronavirus case counts worldwide are already higher in 2021 than they were in 2020. The death toll almost certainly will be.” In addition, the U.S. CDC isn’t even sure how long vaccines will protect people. As they noted, “Although vaccines are effective at keeping you from getting sick, scientists are still learning how well vaccines prevent you from spreading the virus that causes it to others, even if you do not have symptoms. Early data shows that vaccines help keep people with no symptoms from spreading it, but we are learning more as more people get vaccinated. We’re also still learning how long vaccines protect people.” That being the case, vaccine stocks could see even more buy interest, such as Ocugen (OCGN), Pfizer (PFE), Moderna (MRNA), and Vir Technology (VIR). Look at Ocugen for example. The company is about to submit its emergency use authorization (EUA) application to the US FDA for its virus vaccine. “Since we have been in discussions with the FDA since late last year, we do not believe that the FDA’s recently revised guidance regarding EUAs raises any concerns about our ability to submit the EUA for COVAXIN as planned, which is currently in process and which we expect to submit to the FDA in June. We believe that the FDA’s new guidance confirms that Ocugen continues to meet all criteria for submission of an EUA.” [Read More]( Higher Interest Rates are Bad for Stock Markets by [Steve Swanson]( It is a basic investment tenet that investors seek to earn the highest rate of return for the lowest possible risk. Generally, higher risk opportunities provide better rates of return and vice versa. Some of the best historical returns for investors have been earned by owning stocks. The annualized return for the S&P 500 Index (and its predecessor S&P 90 Index) between 1926 and 2012 has been about 10.08%. But stock markets also carry the higher risk of possibly losing your principle investment too. Less risky bank CD’s or government Treasuries carry almost no risk of losing principle because they are guaranteed by the government. With that guarantee however, comes a much smaller rate of return. It is at this juncture where the struggle over asset allocation really begins. Interest rates as defined by the Fed Funds Rate dictate what banks, corporations, and ultimately consumers pay to borrow money. For corporations, their borrowing rate affects their ability to maintain inventory, expand operations, invest in new products, or even buyout competitors. For consumers, it determines how much they will have to pay for mortgages, new cars, home improvements, education, etc. [Read More]( [Joe Duffy’s KeyPoint Market Daily]( June 9, 2021 Elite Wall Street trader, Joe Duffy, is allowing a limited group of future-elite investors into his masterful daily trades at thousands of dollars less than what others charge. When you join today for $1, the first month you'll receive: - Joe Duffy’s daily video newsletter with updates on what's happening in the markets that very day. Rather than watch talking heads for hours on cable, I'll get you up to speed in minutes. - You get weekend updates where I delve more into 'bigger picture' looks at the marketplace. Videos are illustrative, instructive, concise, and un-hedged. No double talk here. - And much, much more! Check out his most recent video here: [Duffys KMD]( [www.tradewins.com]( [Facebook]( [Twitter]( [LinkedIn]( [Youtube]( [Better Business Bureau]( © Copyright 2021 [TradeWins.com](. All rights reserved. TradeWins Publishing, 22C New Leicester Hwy, #117, Asheville, NC 28806 Email: support@iss-trading.com | Phone: 888-233-1431 | Fax: 888-258-4938 PLEASE READ: Auto-trading, or any broker or advisor-directed type of trading, is not supported or endorsed by TradeWins. For additional information on auto-trading, you may visit the SEC’s website: [All About Auto-Trading](, TradeWins does not recommend or refer subscribers to broker-dealers. You should perform your own due diligence with respect to satisfactory broker-dealers and whether to open a brokerage account. You should always consult with your own professional advisers regarding equities and options on equities trading. 1) The information provided by the newsletters, trading, training and educational products related to various markets (collectively referred to as the “Services”) is not customized or personalized to any particular risk profile or tolerance. Nor is the information published by TradeWins Publishing (“TradeWins”) a customized or personalized recommendation to buy, sell, hold, or invest in particular financial products. The Services are intended to supplement your own research and analysis. 2) TradeWins’ Services are not a solicitation or offer to buy or sell any financial products, and the Services are not intended to provide money management advice or services. 3) Past performance is not necessarily indicative of future results. Trading and investing involve substantial risk. Trading on margin carries a high level of risk, and may not be suitable for all investors. Other than the refund policy detailed elsewhere, TradeWins does not make any guarantee or other promise as to any results that may be obtained from using the Services. No person subscribing for the Services (“Subscriber”) should make any investment decision without first consulting his or her own personal financial adviser, broker or consultant. TradeWins disclaims any and all liability in the event anything contained in the Services proves to be inaccurate, incomplete or unreliable, or results in any investment or other loss by a Subscriber. 4) You should trade or invest only “risk capital” – money you can afford to lose. Trading stocks and stock options involves high risk and you can lose the entire principal amount invested or more. 5) All investments carry risk and all trading decisions made by a person remain the responsibility of that person. There is no guarantee that systems, indicators, or trading signals will result in profits or that they will not produce losses. Subscribers should fully understand all risks associated with any kind of trading or investing before engaging in such activities. 6) Some profit examples are based on hypothetical or simulated trading. This means the trades are not actual trades and instead are hypothetical trades based on real market prices at the time the recommendation is disseminated. No actual money is invested, nor are any trades executed. Hypothetical or simulated performance is not necessarily indicative of future results. Hypothetical performance results have many inherent limitations, some of which are described below. Also, the hypothetical results do not include the costs of subscriptions, commissions, or other fees. Because the trades underlying these examples have not actually been executed, the results may understate or overstate the impact of certain market factors, such as lack of liquidity. Simulated trading services in general are also designed with the benefit of hindsight, which may not be relevant to actual trading. In addition, hypothetical trading does not involve financial risk, and no hypothetical trading record can completely account for the impact of financial risk of actual trading. TradeWins makes no representations or warranties that any account will or is likely to achieve profits similar to those shown. 7) No representation is being made that you will achieve profits or the same results as any person providing testimonial. No representation is being made that any person providing a testimonial is likely to continue to experience profitable trading after the date on which the testimonial was provided, and in fact the person providing the testimonial may have experienced losses. 8) The author experiences are not typical. The author is an experienced investor and your results will vary depending on risk tolerance, amount of risk capital utilized, size of trading position and other factors. Certain Subscribers may modify the author methods, or modify or ignore the rules or risk parameters, and any such actions are taken entirely at the Subscriber’s own election and for the Subscriber’s own risk. If you wish to stop receiving our emails or change your subscription options, please [Manage Your Subscription]( TradeWins Publishing, 528 North Country Rd., St. James, NY 11780

EDM Keywords (207)

wrote would world wish whether west website warranties want virus using updates unreliable unfortunately typical trading tradewins trades trade tolerance time thousands testimonial talking symptoms sure supported supplement suitable suggests subscriber submit submission struggle still spreading spent speed something solicitation slowness show services sell seen sec says rules risk return results result responsibility respect research representations representation relevant recommendation recommend provided promise profits process predecessor planned personalized person perform pay parts pandemic overstate options open one offer ocugen obtained noted normal nobody need name much modify minutes meet means may markets market make made luxury love lot loss lose likely life liability letter learning lack kind keeping june juncture investors investment investing invested invest intended instead influx india include impact ignore hypothetical hours hope hindsight happening guaranteed guarantee grab government give get general fly fees fda fact expect executed examples example exactly eua entry enter enjoy engaging endorsed emergence emails election effective earned earn due download disseminated discussions determines described delve defined deaths days date customized currently criteria covaxin costs corporations contributed continue consumers consulting concerns company come click check change cdc causes cable buy broker bothering book blueprint benefit believe beginning based bad author anyone also allowing afford addition actually actions account ability 2021 2020 2012 1926

Marketing emails from tradewins.com

View More
Sent On

08/06/2024

Sent On

08/06/2024

Sent On

08/06/2024

Sent On

07/06/2024

Sent On

07/06/2024

Sent On

07/06/2024

Email Content Statistics

Subscribe Now

Subject Line Length

Data shows that subject lines with 6 to 10 words generated 21 percent higher open rate.

Subscribe Now

Average in this category

Subscribe Now

Number of Words

The more words in the content, the more time the user will need to spend reading. Get straight to the point with catchy short phrases and interesting photos and graphics.

Subscribe Now

Average in this category

Subscribe Now

Number of Images

More images or large images might cause the email to load slower. Aim for a balance of words and images.

Subscribe Now

Average in this category

Subscribe Now

Time to Read

Longer reading time requires more attention and patience from users. Aim for short phrases and catchy keywords.

Subscribe Now

Average in this category

Subscribe Now

Predicted open rate

Subscribe Now

Spam Score

Spam score is determined by a large number of checks performed on the content of the email. For the best delivery results, it is advised to lower your spam score as much as possible.

Subscribe Now

Flesch reading score

Flesch reading score measures how complex a text is. The lower the score, the more difficult the text is to read. The Flesch readability score uses the average length of your sentences (measured by the number of words) and the average number of syllables per word in an equation to calculate the reading ease. Text with a very high Flesch reading ease score (about 100) is straightforward and easy to read, with short sentences and no words of more than two syllables. Usually, a reading ease score of 60-70 is considered acceptable/normal for web copy.

Subscribe Now

Technologies

What powers this email? Every email we receive is parsed to determine the sending ESP and any additional email technologies used.

Subscribe Now

Email Size (not include images)

Font Used

No. Font Name
Subscribe Now

Copyright © 2019–2024 SimilarMail.